Pharma Market Access Insights - from Mtech Access

60 Folgen

1. NHS primary care panel – the GP Contract and Operational Planning Guidance

   Vom: 10.9.2024
2. Engage NHS healthcare decision-makers with RWD

   Vom: 12.8.2024
3. Market access and reimbursement in Canada – changes at CADTH

   Vom: 20.6.2024
4. Rare Disease market access in the MENA and Nordic regions

   Vom: 10.5.2024
5. How does funding flow in NHSE Regions?

   Vom: 9.4.2024
6. NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)

   Vom: 9.4.2024
7. De-mystifying health economic model classifications and structures

   Vom: 22.3.2024
8. Evidence strategy for Medical Technologies and Diagnostics

   Vom: 12.3.2024
9. How to set your Pharma or Medtech product up for success in the US market

   Vom: 26.2.2024
10. What's happening with specialised commissioning in the NHS?

    Vom: 12.2.2024
11. Integrated care in NHS Wales – what can England learn from its neighbour?

    Vom: 17.1.2024
12. Market access in Italy: Reforms at AIFA

    Vom: 18.12.2023
13. Unmet need in NHS primary care – How can industry best support PCN leaders?

    Vom: 28.11.2023
14. Population health management: a community effort across health and life sciences

    Vom: 1.11.2023
15. Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

    Vom: 26.10.2023
16. 6 areas of UK health policy for Medtech to pay attention to

    Vom: 16.10.2023
17. Market access in the German speaking markets

    Vom: 29.8.2023
18. The role of nursing in driving digital change in the NHS

    Vom: 26.7.2023
19. Market access for digital therapies and digital medicines

    Vom: 19.7.2023
20. A global market access journey in cannabinoid pharmaceuticals

    Vom: 17.6.2023